CMS Is a Step Closer to Saying How It Will Fix Medicare Drug Payment Cuts for 340B Hospitals

OMB
CMS sent its proposed remedy for illegal Medicare Part B drug payment cuts for 340B hospitals to the White House for clearance to be released.

The U.S. Centers for Medicare & Medicaid Services has sent its proposed remedy for almost five years of illegal Medicare Part B drug payments cuts for 340B hospitals to the White House for clearance to be published in the Federal

Read More »

CMS Proposes Rules That Addresses 340B Duplicate Discounts in Medicaid Managed Care

CMS
CMS proposes adding information to Medicaid managed care beneficiaries' insurance cards to facilitate 340B duplicate discount prevention.

The U.S. Centers for Medicare & Medicaid Services wants to make Medicaid managed care organizations use Medicaid-specific codes and group numbers on beneficiary insurance cards to help states, MCOs, and 340B covered entities avoid invoicing manufacturers for prohibited duplicate 340B

Read More »

How 340B Covered Entities are Disrupting the PBM and Preferred Pharmacy Landscape for Community Health Plans

SPONSORED CONTENT

The 340B drug pricing program, which allows eligible healthcare providers known as covered entities to purchase medications at a reduced price, has been an incredibly valuable tool for providing affordable healthcare to underserved populations. However, the benefits of the 340B program go beyond just reducing the cost of medications. Covered entities

Read More »

340B Providers Don’t Systematically Over-Prescribe Brand Drugs for Profit, JAMA Study Says

JAMA
Research published in JAMA "found no meaningful difference in overall generic prescribing rates" between 340B and non-340B providers.

340B-eligible providers prescribe generic drugs at the same overall rate as non-340B providers, a study published in JAMA Health Forum found. “We found no evidence that 340B-eligible prescribers were systematically overprescribing brand-name drugs to generate revenue,” the authors said.

Read More »

Arkansas 340B Contract Pharmacy Law Trespasses on Federal “Closed System,” PhRMA Tells Court

PhRMA v. McClain
Arkansas' 340B contract pharmacy law has no place in the federal 340B “closed system,” PhRMA told a federal appeals court.

Arkansas’ 340B contract pharmacy law, for now the only state law of its kind, has no place in the federal 340B “closed system,” Pharmaceutical Research and Manufacturers of America (PhRMA) recently told a federal appeals court.

“340B is a closed

Read More »

340B Report Publisher and CEO: Is a Contract Pharmacy Breakthrough at Hand?

Breakthrough
Hospital groups' decision to back federal 340B contract pharmacy legislation could be a long-awaited breakthrough, 340B Report Publisher and CEO Ted Slafsky says.

Hospital groups’ decision to support letting Congress end the 340B contract pharmacy standoff could be the breakthrough the field has been waiting for, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Verity Solutions.

“National hospital

Read More »

House GOP Rejects Democrats’ Push to Link 340B Transparency and Contract Pharmacy

E&C 340B
House E&C Democrat Scott Peters (Calif.) spoke in favor of, and fellow Democrat Debbie Dingell (Mich.) spoke against, a Republican bill to impose reporting requirements on 340B DSH hospitals.

Congressional GOP backers of federal reporting requirements for 340B hospitals yesterday rejected Democratic arguments that fairness dictates that those requirements be paired with 340B contract pharmacy requirements for drug manufacturers.

U.S. House Energy & Commerce Committee Republicans, joined by just

Read More »

340B Grantees Need More Scrutiny as Drug Margins Rise, Gilead-funded Study Says

Gilead BGR study
340B contract pharmacy arrangements rose 252% for grantee covered entities between 2017 to 2022 compared to 194% for hospitals, a new drug company-funded study found.

Health centers and other federal grantees’ 340B savings and how they use them need more scrutiny, as these covered entities account for a large chunk of total 340B drug sales and their margins are keeping pace with those of hospitals,

Read More »

3 Tips for Navigating the Current 340B Environment

SPONSORED CONTENT

Many people have been losing sleep thinking about how they should move forward in the current 340B environment. Over the last 18 months, it has felt like an external force is around every corner, pushing or pulling covered entities into new areas of discomfort.

During these turbulent times, it can help to find partners

Read More »

340B Advocacy Group CV340B Plans March on Capitol Hill July 12

CV340B
Community Voices for 340B (CV340B) on July 12 is holding its second annual Defend 340B March on Capitol Hill. The first was in August 2022.

340B grassroots group Community Voices for 340B (CV340B) has announced plans to hold its second annual Defend 340B March on Capitol Hill July 12.

A primary goal of the event is to raise awareness among lawmakers about 340B’s importance

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report